Literature DB >> 11779525

In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin.

David J Cohen1, J Conor O'Shea, Cindy M Pacchiana, Glenn Levine, Ian Sarembock, James Slater, Eric Conn, Jack Smith, James E Tcheng.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11779525     DOI： 10.1016/s0002-9149(01)02165-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  5 in total

1.  Cost-effectiveness of adjunctive eptifibatide in patients undergoing coronary stenting in Germany.

Authors:  Sarah Dewilde; Bernd Brüggenjürgen; Christoph Nienaber; Jochen Senges; Robert Welte; Stefan N Willich
Journal:  Eur J Health Econ       Date:  2011-04-12

Review 2.  Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.

Authors:  Monique P Curran; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes.

Authors:  Nick Bosanquet; Bengt Jönsson; Keith A A Fox
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

4.  Eptifibatide: The evidence for its role in the management of acute coronary syndromes.

Authors:  Ibrahim Shah; Shakeel O Khan; Surender Malhotra; Tim Fischell
Journal:  Core Evid       Date:  2010-06-15

Review 5.  Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes.

Authors:  Greg L Plosker; Tim Ibbotson
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.